What You Should Know: - 23andMe, a genetic health and biopharmaceutical company launched Health Action Plan, a new digital tool for 23andMe+ members that draws on results from genetic reports, health history survey data, as well as blood and biomarker data to provide a uniquely tailored set of health recommendations out of hundreds of options. - Health Action Plan is a helpful first step when it comes to prevention and early risk detection. It offers customers specific actions and
Read More
Digital Biomarkers
The Future of Biomarker-Based Therapy for Mental Disorder Care
We are living in a mental health epidemic. An estimated 26 percent of Americans ages 18 and older – about one in four adults – suffer from a diagnosable mental disorder in a given year. Among mental disorders, cases of PTSD are on the rise. Roughly five percent of American adults suffer from PTSD in any given year and more than 13 million Americans reported PTSD in 2020 – most of whom are women. Standard PTSD treatments most often come in the form of pharmacotherapy or psychotherapy and include
Read More
Mount Sinai Researchers Identify Biomarker That Tracks Recovery From Treatment-Resistant Depression
What You Should Know: A team of leading clinicians, engineers, and neuroscientists has made a groundbreaking discovery in the field of treatment-resistant depression. By analyzing the brain activity of patients undergoing deep brain stimulation (DBS), a promising therapy involving implanted electrodes that stimulate the brain, the researchers identified a unique pattern in brain activity that reflects the recovery process in patients with treatment-resistant depression.This pattern, known as
Read More
ALZpath Secures Funding for Blood-Based Biomarker Testing for Alzheimer’s Disease Detection
What You Should Know: - ALZpath, a developer of blood-based diagnostic biomarker testing for Alzheimer's disease detection receives funding from the Alzheimer’s Drug Discovery Foundation (ADDF)’s Diagnostics Accelerator to accelerate the clinical availability of ALZpathDx as a laboratory developed test (LDT). - ALZpathDx is a novel, proprietary assay for blood-based measurement of phosphorylated tau at threonine 217 (pTau217), a highly accurate, diagnostic biomarker for
Read More
Sonde Health Secures $19.25M for Voice-Based Health Monitoring
What You Should Know: - Sonde Health, a Boston, MA-based health technology company committed to bringing accessible health monitoring to everyone raises $19.25 million in a Series B investment round led by Partners Investment, with participation from NEOM Company, KT Corporation, and existing investors, including co-founder PureTech Health and M Ventures. - The AI vocal biomarker company will use the funding to accelerate its commercial growth, expand its platform into new health
Read More
How Biosensing Tech Can Alleviate Dehydration in Older Adults
For most adults, the first sign of dehydration is feeling thirsty. However, as we age, our thirst sensation naturally weakens, which means older people may not know that they need more fluids until they’re typically underhydrated, putting them at a higher risk of clinical dehydration. Other age-related physiological changes can also impact a person’s ability to remain hydrated, such as a decline in kidney function. Indeed, renal function begins to diminish around the age of 50. This is due
Read More
NeuroSense Therapeutics and NeuraLight Collaborate to Detect ALS Oculometric Biomarkers
What You Should Know: - NeuroSense Therapeutics Ltd., a company developing treatments for severe neurodegenerative diseases, and NeuraLight, a company developing objective and sensitive biomarkers for neurological disorders, today announced a collaboration to advance the science of digital biomarkers in the detection and monitoring of neurological diseases including amyotrophic lateral sclerosis (ALS). - This agreement marks NeuraLight’s first clinical trial and comes on the heels of
Read More
Imagene Raises $21.5M to Expand Image-Based Biomarker Detection for Precision Medicine
What You Should Know: - Imagene AI, an emerging leader in the field of AI-based precision medicine for cancer, today announced it raised $21.5 million, comprising $3M in seed funding led by Blumberg Capital and an $18.5M Series A round led by renowned technology-driven cancer medicine investors Larry Ellison, Dr. David Agus, and AI imaging space pioneer Eyal Gura. - The use of AI-based molecular testing in cancer diagnostics is revolutionizing patient care by offering a new level of
Read More
Labcorp & Medidata to Co-Develop Digital Biomarkers & Expand Decentralized Clinical Trials
What You Should Know: - Medidata, a Dassault Systèmes company, today announced that Labcorp, a leading global life sciences company, has selected Medidata's technology platform to extend their 14-year partnership, the foundation of their initiative to co-develop digital biomarkers and expand the use and functionality of decentralized clinical trials. Labcorp Drug Development has developed its offerings on Medidata technologies, starting with Rave EDC
Read More
VivoSense Raises $25M for Wearable Sensor Biomarkers to Advance Clinical Trials
What You Should Know: - VivoSense, an agile end-to-end scientific solutions company developing novel digital endpoints from wearable sensor data raises $25 Million in Series A funding. - The financing will accelerate the development of novel digital biomarkers and improve digital clinical outcome assessments. VivoSense will also use this financing to expand and refine its informatics platform for data analysis from wearable and connected technologies to deliver validated digital
Read More
